Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer
NCT01246427 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 138
Last updated 2016-09-14
Summary
The purpose of this study is to evaluate the efficacy of a homeopathic treatment (BRN01) in reducing hot flash scores after 4 weeks of treatment.
Conditions
Interventions
- DRUG
-
BRN01
2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
- DRUG
-
2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
Sponsors & Collaborators
-
BOIRON
collaborator INDUSTRY -
Centre Leon Berard
lead OTHER
Principal Investigators
-
Pierre Etienne Heudel, MD · Centre Leon Berard, France
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-01-31
- Primary Completion
- 2014-05-31
- Completion
- 2014-11-30
Countries
- France
Study Locations
More Related Trials
-
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
NCT06929325 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
NCT04460898 ·Status: COMPLETED
-
A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
NCT05628870 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
NCT02595762 ·Status: COMPLETED
-
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
NCT01463891 ·Status: COMPLETED
-
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
NCT04060862 ·Status: TERMINATED ·Phase: PHASE1
-
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
NCT00993642 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
NCT05697146 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.
NCT07320521 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
NCT04498481 ·Status: COMPLETED
-
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
NCT06900647 ·Status: RECRUITING ·Phase: PHASE1
-
AT13387 in Adults With Refractory Solid Tumors
NCT01246102 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
NCT00034125 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
NCT04937660 ·Status: COMPLETED
-
Breast Cancer With Over-expression of erbB2-BRAINSTORM
NCT01064349 ·Status: COMPLETED
-
Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
NCT05578053 ·Status: RECRUITING
-
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239 ·Status: RECRUITING ·Phase: PHASE3
-
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
NCT01240421 ·Status: APPROVED_FOR_MARKETING
-
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
NCT05584644 ·Status: COMPLETED
-
Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
NCT02443428 ·Status: COMPLETED
-
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
NCT04913532 ·Status: COMPLETED ·Phase: NA
-
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
NCT04671615 ·Status: COMPLETED
-
A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
NCT06235931 ·Status: RECRUITING ·Phase: NA
-
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3